This follow-up report is submitted to fda in accord with applicable regulations ¿ and as indicated by terumo cardiovascular systems in the initial report submitted to the fda on february 17, 2021.Upon further investigation of the reported event, the following information is new and/or changed: d4 (additional device information - added exp date).D9 (device availability - added date returned to manufacturer).G3 (date received by manufacturer).G6 (indication that this is a follow-up report).H2 (follow-up due to additional information and device evaluation).H3 (device evaluated by manufacturer).H4 (device manufacture date).H6 (identification of evaluation codes 10, 11, 3331, 4210, 4307).Type of investigation #1: 10 - testing of actual/suspected device.Type of investigation #2: 11 - testing of device from same lot/batch retained by manufacturer.Type of investigation #3: 3331 - analysis of production records.Investigation findings: 4210 - leakage/seal.Investigation conclusions: 4307 - cause traced to component failure.The complaint sample was returned for investigation with no anomalies noted on the device.The sample was then manually run through the ops leak tests to ensure each component of the device is functioning as normal and passed testing.However, a photo provided did show evidence of a valve leak.All ops valves are subjected to a 100% leak test that undergoes 5 separate programs to test that each component in the valve is functioning properly.The retention sample was visually inspected with no anomalies noted on the device.It was then manually run through the ops leak tests to ensure each component of the device is functioning as normal.The retention sample passed the leak tests.All available information has been placed on file in quality management for appropriate tracking, trending, and follow-up.
|